GSK Admits Voltaren Marketing Misled Australian Consumers, Now Facing Financial Penalty
Executive Summary
GSK has admitted misleading Australian consumers with the marketing of its Voltaren range by claiming Osteo Gel was specifically formulated for treating osteoarthritis conditions, and was more effective than Emulgel to treat those conditions, when the two products were identically formulated. While a change to Osteo Gel's packaging has since satisfied Australia's Federal Court, GSK is still facing a financial penalty for its earlier conduct.
You may also be interested in...
GSK And Novartis Hit With $3m Fine In Australia For Misleading Voltaren Claims
Marketing Voltaren Osteo Gel as more effective for treating osteoarthritis than the identically formulated Voltaren Emugel has landed GSK and Novartis with a substantial fine for breaching Australian Consumer Law.
GSK/Pfizer Tie-Up Granted Clearance In Australia and New Zealand
A two-month-long inquiry into GSK and Pfizer's proposed consumer health joint venture by Australia's Competition and Consumer Commission has found no notable areas of concern for the country's OTC market. Meanwhile, New Zealand has also given the go-ahead for the combination.
GSK To Unlock E-Commerce Growth In China With Alibaba Tie-Up
GSK will use Alibaba’s big data expertise to identify new consumer insights, while also taking advantage of the Chinese firm’s e-commerce platforms to reach a wider audience. Alongside this, the partners will provide online health consultations and self-care education to Chinese consumers.